ALZN - Alzamend Neuro, Inc.
1.14
0.005 0.439%
Share volume: 31,213
Last Updated: Tue 04 Feb 2025 10:00:00 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.37%
PREVIOUS CLOSE
CHG
CHG%
$1.14
0.00
0.00%
View ratios
| Fiscal Date | 2023-01-31 | 2023-04-30 | 2024-01-31 | 2024-04-30 | 2024-07-31 | 2024-10-31 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q3 2023 | Q4 2023 | Q3 2024 | Q4 2024 | Q1 2024 | Q2 2024 | |
| Report Date | 2023-03-15 | 2024-07-30 | 2024-03-25 | 2024-12-11 | 2024-09-11 | 2024-12-11 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | |||||
| Operating expenses | 5.424 M | 3.305 M | 2.660 M | 850.062 K | 962.405 K | 1.358 M | |
| Selling general and admin | 2.535 M | 1.657 M | 751.173 K | 666.632 K | 755.834 K | 1.047 M | |
| Research and development | 2.889 M | 1.648 M | 1.909 M | 183.430 K | 206.571 K | 311.088 K | |
| Total expenses | 5.424 M | 3.305 M | 2.660 M | 850.062 K | 962.405 K | 1.358 M | |
| -39.06% | -19.52% | -68.04% | 13.22% | 41.11% | |||
| Operating income | -5.424 M | -3.305 M | -2.660 M | -850.062 K | -962.405 K | -1.358 M | |
| Ebit | -5.424 M | -3.305 M | -2.660 M | -850.062 K | -962.405 K | -1.362 M | |
| Pretax income | -5.426 M | -3.306 M | -2.662 M | -851.529 K | -974.411 K | -1.365 M | |
| -39.08% | -19.46% | -68.02% | 14.43% | 40.09% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -5.426 M | -3.306 M | -2.662 M | -851.529 K | -974.411 K | -1.362 M | |
| 39.08% | 19.46% | 68.02% | -14.43% | -39.73% |